Alba Therapeutics Corp., of Baltimore, appointed Betsy Van Parijs senior vice president of clinical development and medical affairs.

Algeta ASA, of Oslo, Norway, appointed Peter Harris chief medical officer.

Agendia BV, of Amsterdam, the Netherlands, appointed Hessel Lindenbergh chairman of its board.

Athersys Inc., of Cleveland, elected Lorin Jeffry Randall to its board and named him chairman of the audit committee.

BioAlliance Pharma SA, of Paris, appointed Christian Auclair chief scientific officer.

BioSante Pharmaceuticals Inc., of Lincolnshire, Ill., appointed Joy Thomas vice president of corporate development.

Biotica Technology Ltd., of Cambridge, UK, named Edward Hodgkin CEO.

Bradmer Pharmaceuticals Inc., of Toronto, appointed Paul Van Damme chief financial officer.

Cadence Pharmaceuticals Inc., of San Diego, named Malvina Laudicina vice president of regulatory affairs and quality assurance.

Ceapro Inc., of Edmonton, Alberta, named Gilles Gagnon to its board.

Cepheid Inc., of Sunnyvale, Calif., named Alex van Belkum, Carlo Croce, Herbert Fritsche, Joe Gray, Patrick Murray, Franklyn Prendergast, David Relman and Michael Sarosdy to its scientific advisory board.

Codexis Inc., of Redwood City, Calif., elected Bruce Pasternack to its board.

ConjuChem Biotechnologies Inc., of Montreal, appointed Jean Silveri vice president, general counsel.

Crucell NV, of Leiden, the Netherlands, appointed Cees de Jong chief operating officer.

CytRx Corp., of Los Angeles, appointed Stephen DiPalma chief financial officer.

Egalet A/S, of Copenhagen, Denmark, named Michael Fiorini chairman and appointed Peter Nordkild CEO.

Elan Corp. plc, of Dublin, Ireland, named Jonas Frick and Giles Kerr nonexecutive directors.

Endo Pharmaceuticals Inc., of Chadds Ford, Pa., appointed Nancy Wysenski chief operating officer.

Genaera Corp., of Plymouth Meeting, Pa., named Louis Aronne, Mitchell Lazar, F. Xavier Pi-Sunyer, David D'Alession, Thomas Wadden, Nicholas Tonks, Samuel Klein, Rudolph Leibel, Pauline Maki and Martin Graham to its trodusquemine scientific advisory board.

Immtech Pharmaceuticals Inc., of New York, said Gen. Wesley Clark joined as strategic advisor.

Interleukin Genetics Inc., of Waltham, Mass., named Thomas Gerson chief financial officer, appointed James Weaver chairman and named Nazneed Aziz vice president of research and development.

InterMune Inc., of Brisbane, Calif., elected Louis Drapeau to its board.

Medivir AB, of Stockholm, Sweden, appointed Stefan Martensson vice president of sales and marketing.

Micromet Inc., of Bethesda, Md., appointed Mark Reisenauer senior vice president and chief commercial officer.

Millennium Biotechnologies Group Inc., of Basking Ridge, N.J., elected Mark Mirken president and chief operating officer of the company and its subsidiary, Millennium Biotechnologies Inc.

Modern Biosciences plc, of London, named Clive Dix nonexecutive chairman.

Morgenthaler Ventures, of Menlo Park, Calif., added Hank Plain as partner.

Neurogen Corp., of Branford, Conn., appointed Stephen David president.

NeurogesX Inc., of San Carlos, Calif., appointed Bruce Peacock to its board.